CVS caremark™ {{PANUMCODE}}

Xeljanz, Xeljanz XR

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: {{MEMFIRST}} {{MEMLAST}} **Date**: {{TODAY}}
Patient's ID: {{MEMBERID}} **Patient's Date of Birth:** {{MEMBERDOB}}
Physician's Name: {{PHYFIRST}} {{PHYLAST}}
Specialty: _____, **NPI#:** _____
Physician Office Telephone: {{PHYSICIANPHONE}} **Physician Office Fax:** {{PHYSICIANFAX}}
Request Initiated For: {{DRUGNAME}}

1. What is the prescribed quantity and frequency?
   a) ❑ Xeljanz 5 mg Quantity and frequency: _____
   b) ❑ Xeljanz 10 mg Quantity and frequency: _____
   c) ❑ Xeljanz 1 mg/mL Quantity and frequency: _____
   d) ❑ Xeljanz XR 11 mg Quantity and frequency: _____
   e) ❑ Xeljanz XR 22 mg Quantity and frequency: _____
   f) ❑ Other _____

2. What is the diagnosis?
   ❑ Moderately to severely active rheumatoid arthritis (RA)
   ❑ Active psoriatic arthritis (PsA)
   ❑ Moderately to severely active ulcerative colitis (UC)
   ❑ Active articular juvenile idiopathic arthritis, *please specify:*
      ❑ Polyarticular juvenile idiopathic arthritis
      ❑ Oligoarticular juvenile idiopathic arthritis
   ❑ Other _____

3. What is the ICD-10 code? _____

4. What is patient's weight? _____ kg

Section A: Preferred Product

5. These are the preferred products for which coverage is provided for the treatment of the following indications:
   a) Psoriatic arthritis: **Cosentyx, Enbrel, Humira, Otezla, Remicade, Simponi Aria**
   b) Ulcerative colitis: **Humira, Remicade**

   Can the patient's treatment be switched to a preferred product?
   ❑ Yes - Please indicate:_____ ***If Yes, please call 1-866-814-5506 to have the updated form faxed to your office OR you may complete the PA electronically (ePA). You may sign up online via CoverMyMeds at: www.covermymeds.com/epa/caremark/ or call 1-866-452-5017.***
   ❑ No
   ❑ Not applicable - Request for condition not listed above, *skip to Section B: All Requests*

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

6. Is this request for continuation of therapy with the requested product? ❑ Yes ❑ No *If No, skip to #8*

7. Is the patient currently receiving the requested product through samples or a manufacturer's patient assistance program? If unknown, answer Yes. ❑ Yes ❑ No *If No, skip to Section B: All Requests*

8. Does the patient have a documented inadequate response or intolerable adverse event to any of the following products? *Indicate ALL that apply.* ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
   - ❑ Cosentyx: ❑ Inadequate response ❑ Intolerable adverse event
   - ❑ Enbrel: ❑ Inadequate response ❑ Intolerable adverse event
   - ❑ Humira: ❑ Inadequate response ❑ Intolerable adverse event
   - ❑ Otezla: ❑ Inadequate response ❑ Intolerable adverse event
   - ❑ No - None of the above

9. Does the patient have one of the following documented clinical reasons to avoid the preferred products that are TNF inhibitors (Enbrel and/or Humira)? ***ACTION REQUIRED: If Yes, attach supporting chart note(s).***
   - ❑ Yes - History of demyelinating disorder - *Indicate drug(s):* _____
   - ❑ Yes - History of congestive heart failure- *Indicate drug(s):* _____
   - ❑ Yes - History of hepatitis B virus infection- *Indicate drug(s):* _____
   - ❑ Yes - Autoantibody formation/lupus-like syndrome (attributed to TNF inhibitor) *Indicate drug(s):* _____
   - ❑ Yes - Risk of lymphoma- *Indicate drug(s):* _____
   - ❑ No - none of the above
   - ❑ Not applicable - requested medication is a TNF inhibitor

Section B: All Requests

10. Will the requested drug be used in combination with any other biologic (e.g., Humira), targeted synthetic disease-modifying antirheumatic drug (DMARD) (e.g., Otezla, Rinvoq, Olumiant), or potent immunosuppressant such as azathioprine or cyclosporine? ❑ Yes ❑ No

11. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic DMARD (e.g., Rinvoq, Olumiant) associated with an increased risk of tuberculosis? *If Yes, skip to #13* ❑ Yes ❑ No

12. Has the patient had a tuberculosis (TB) test (e.g., tuberculosis skin test [PPD], interferon-release assay [IGRA], chest x-ray) within 6 months of initiating therapy? *If Yes, skip to #15* ❑ Yes ❑ No

13. Does the patient have risk factors for tuberculosis (TB) (e.g., persons with close contact to people with infectious TB disease; persons who have recently immigrated from areas of the world with high rates of TB [e.g., Africa, Asia, Eastern Europe, Latin America, Russia]; children less than 5 years of age who have a positive TB test; groups with high rates of TB transmission [e.g., homeless persons, injection drug users, persons with HIV infection], or persons who work or reside with people who are at an increased risk for active TB [e.g., hospitals, long-term care facilities, correctional facilities, homeless shelters])? ❑ Yes ❑ No *If No, skip to #18*

14. Has the patient been tested for tuberculosis (TB) within the previous 12 months? ❑ Yes ❑ No

15. What were the results of the tuberculosis (TB) test? *If Negative, skip to #18*
    ❑ Positive for TB ❑ Negative for TB ❑ Unknown

16. Does the patient have latent or active tuberculosis (TB)? ❑ Latent ❑ Active ❑ Unknown

17. Has treatment for latent tuberculosis (TB) infection been initiated or completed?
    ❑ Yes - treatment initiated ❑ Yes - treatment completed ❑ No

18. Is this request for continuation of therapy with the requested drug? ❑ Yes ❑ No *If No, skip to #20*

19. Is the patient currently receiving the requested drug through samples or a manufacturer's patient assistance program? ❑ Yes ❑ No, *skip to #21* ❑ Unknown

20. *If patient's diagnosis is psoriatic arthritis,* will the requested drug be used in combination with a conventional synthetic DMARD? *If Yes or No, no further questions.* ❑ Yes ❑ No
    ❑ Not applicable, diagnosis is NOT psoriatic arthritis, *continue to #21*

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155

21. Has the patient achieved or maintained positive clinical response as evidenced by low disease activity or improvement in signs and symptoms since starting treatment with the requested drug? ❑ Yes ❑ No

Complete the following section based on the patient's diagnosis, if applicable.

Section C: Rheumatoid Arthritis

22. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic DMARD (e.g., Rinvoq, Olumiant) that is indicated for moderately to severely active rheumatoid arthritis?
If Yes, no further questions ❑ Yes ❑ No

23. Has the patient experienced an inadequate response after at least 3 months of treatment with methotrexate at a dose greater than or equal to 20 mg per week? *If Yes, no further questions* ❑ Yes ❑ No

24. Has the patient experienced intolerance to methotrexate? *If Yes, no further questions* ❑ Yes ❑ No

25. Does the patient have a contraindication to methotrexate? ❑ Yes ❑ No
If Yes, indicate the contraindication: _____

Section D: Ulcerative Colitis

26. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) indicated for the treatment of moderately to severely active ulcerative colitis? *If Yes, skip to #31* ❑ Yes ❑ No

27. Has the patient been hospitalized for acute, severe ulcerative colitis (e.g., continuous bleeding, severe toxic symptoms, including fever and anorexia)? *If Yes, skip to #31* ❑ Yes ❑ No

28. Has the patient had an inadequate response with at least one tumor necrosis factor inhibitor (TNF-i)?
If Yes, skip to #31 ❑ Yes ❑ No

29. Has the patient experienced an intolerance with at least one tumor necrosis factor inhibitor (TNF-i)?
If Yes, skip to #31 ❑ Yes ❑ No

30. Does the patient have a contraindication to a tumor necrosis factor inhibitor (TNF-i)? ❑ Yes ❑ No

31. Is the request for induction or maintenance of remission?
❑ Induction ❑ Maintenance *If Maintenance, skip to #33*

32. Will the prescribed treatment for induction of remission exceed a duration of 16 weeks?
❑ Yes ❑ No *No further questions*

33. Is the patient experiencing a loss of response during treatment for maintenance of remission? ❑ Yes ❑ No

34. Will the lowest effective dose be utilized and limited to the shortest duration needed? ❑ Yes ❑ No

Section E: Articular Juvenile Idiopathic Arthritis

35. Has the patient ever received (including current utilizers) a biologic (e.g., Humira) or targeted synthetic disease-modifying antirheumatic drug indicated for active articular juvenile idiopathic arthritis?
If Yes, no further questions ❑ Yes ❑ No

36. Has the patient had an inadequate response to methotrexate or another non-biologic DMARD administered at an adequate dose and duration? *If Yes, no further questions* ❑ Yes ❑ No

37. Does the patient have any of the following risk factors? ❑ Yes ❑ No
a) positive rheumatoid factor b) positive anti-cyclic citrullinated peptide antibodies c) pre-existing joint damage

38. Does the patient meet any of the following? ❑ Yes ❑ No
a) high-risk joints are involved (e.g., cervical spine, wrist, or hip) b) high disease activity
c) high risk for disabling joint disease

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit, CVS Caremark Prior Authorization Fax: 1-866-249-6155